CN116239643A - Engliflozin intermediate compound - Google Patents

Engliflozin intermediate compound Download PDF

Info

Publication number
CN116239643A
CN116239643A CN202111516828.9A CN202111516828A CN116239643A CN 116239643 A CN116239643 A CN 116239643A CN 202111516828 A CN202111516828 A CN 202111516828A CN 116239643 A CN116239643 A CN 116239643A
Authority
CN
China
Prior art keywords
compound
reaction
preparation
temperature
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111516828.9A
Other languages
Chinese (zh)
Inventor
张贵民
闫路林
时江华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong New Time Pharmaceutical Co Ltd
Original Assignee
Shandong New Time Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong New Time Pharmaceutical Co Ltd filed Critical Shandong New Time Pharmaceutical Co Ltd
Priority to CN202111516828.9A priority Critical patent/CN116239643A/en
Publication of CN116239643A publication Critical patent/CN116239643A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention belongs to the technical field of drug synthesis, and particularly relates to an englitazone intermediate compound. The invention takes (S) -4- ((tetrahydrofuran-3-yl) oxy) benzoyl chloride as an initial material to react with a compound III to obtain a new intermediate compound V of the engagliflozin. The invention also provides a method for preparing the englitjing by deprotection and reduction of the novel intermediate compound. The new intermediate provided by the invention has the advantages of simple synthesis method, short synthesis route for preparing the englitjing by using the new intermediate, high yield, mild reaction conditions and stable process, and is suitable for mass industrialized production.

Description

Engliflozin intermediate compound
Technical Field
The invention belongs to the technical field of drug synthesis, and particularly relates to an englitazone intermediate compound.
Background
Engliflozin (empagliflozin), chemical name (2S, 3R,4R,5S, 6R) -2- [3- [4- [ (S) -tetrahydrofurane-3-yloxy ] benzyl ] -4-chlorophenyl ] -6-hydroxymethyl-epoxyhexane-3, 4, 5-triol, co-developed by Boringer' S Johner company and Gift, first approved by European drug administration (EMA) for 5 months in 2014, is an SGLT2 hypoglycemic drug which effectively reduces blood glucose, improves insulin sensitivity and islet beta cell function by a mechanism independent of insulin secretion and insulin action, and can reduce cardiovascular disease risk, heart disease and stroke for the first time, and has molecular weight: 450.91, CAS registry number 864070-44-0, having the following structural formula:
Figure BDA0003397573290000011
the literature reports a large number of synthetic methods for enggliflozin, but the ideas are about the same, and mainly include the following:
the method comprises the following steps: U.S. Pat. No. 3, 11406971 uses compound 2, D-glucolactone as raw material, and reacts with trimethylchlorosilane under the catalysis of N-methylmorpholine to obtain key intermediate 2,3,4, 6-tetra-O-trimethylsilyl-D-glucolactone. 5-bromo-2-chlorobenzoic acid is used as a raw material, and reacts with oxalyl chloride under the catalysis of N, N-dimethylformamide to obtain a compound 7, the compound 7 directly undergoes a friedel-crafts acylation reaction with anisole to obtain a compound 8, the compound 8 is reduced in a solution system of triethylsilane and boron trifluoride diethyl ether to obtain a compound 9, the compound 9 is demethylated to obtain a compound 10, and the compound 10 is subjected to the action of triethylamine and 4-dimethylaminopyridine, and TMS is used for protecting the hydroxyl of the compound 10 to obtain a compound 11. Under the protection of argon, carrying out lithium-bromine exchange on a compound 11 and tertiary butyl lithium at-80 ℃ and then carrying out nucleophilic substitution reaction on the compound 11 and tertiary butyl lithium and an intermediate 3, removing TMS protecting groups under an acidic condition to obtain two configuration products 12, removing methoxy groups of the 12 to obtain a compound 13, acetylating the compound 13 by acetic anhydride and then recrystallizing the compound 13 in ethanol to obtain a pure beta conformation product 14, deacetylating the compound 14 under a strong base condition to obtain a compound 15, and carrying out SN (R) -3- (4-methylbenzenesulfonyloxy) tetrahydrofuran on the compound 15 under the action of cesium carbonate 2 Substitution reaction to obtain the target product Engliflozin I, wherein the synthetic route is as follows:
Figure BDA0003397573290000021
the method has long synthetic route and complex operation; the dangerous reagent n-butyllithium is used, the TMS protected glucolactone is unstable, anhydrous and anaerobic conditions are required to be strictly controlled, and the reaction conditions are very harsh; the epimer generated by the route needs to be purified twice, has lower yield and is not beneficial to industrial production.
The second method is as follows: U.S. patent US14770415 and chinese patent application CN1051531374, namely alpha-D-glucose is taken as a raw material, under the protection of nitrogen, pivaloyl chloride and lithium bromide react to generate pivaloyl bromide, and zinc bromide and a compound 4 are added to react to obtain a key intermediate 2,3,4, 6-O-tetrapivaloyl-alpha-D-bromopyranose 5. Obtaining an intermediate 8 according to the route of the first method, reducing the intermediate 8 by sodium borohydride/aluminum trichloride to obtain a compound 9, reacting the compound 9 with an organometallic reagent n-hexyl n-dibutyl magnesium lithium to realize selective magnesium-bromine exchange, then carrying out magnesium-zinc exchange with zinc bromide-lithium bromide, finally carrying out coupling reaction with the compound 5 to obtain an intermediate 16, demethylating the intermediate 16 under the action of boron tribromide to obtain a compound 17, and carrying out SN (N) reaction between the compound 17 and (R) -3-iodotetrahydrofuran under alkaline conditions 2 Substitution reaction to obtain the target I:
Figure BDA0003397573290000022
the method has the advantages of short synthetic route, low-cost and easily-obtained raw materials, mild reaction conditions, good stereoselectivity when pivaloyl is used for protecting, and high yield, but the organic metal reagent n-hexyl n-dibutyl magnesium lithium is not easily obtained.
And a third method: chinese patent application CN105399735 takes compound 18, namely 5-iodine-2-chlorobenzoic acid as raw material, and under the catalysis of DMF, the compound 18 reacts with oxalyl chloride to obtain compound 19, the compound 19 reacts with fluorinated benzene under the participation of Lewis acid aluminum trichloride to generate Friedel-crafts acylation reaction to obtain compound 20, and the compound 20 reacts with (S) -3-hydroxytetrahydrofuran under the action of strong alkali potassium tert-butoxide to generate SN 2 Nucleophilic substitution reaction to obtain compound 21, reducing the compound 21 by sodium borohydride-aluminum trichloride system to obtain compound 22, reacting the compound 22 with n-butyllithium and zinc bromide-lithium bromide, coupling with compound 5 to selectively generate beta conformational product 23, and removing pivaloyl from the compound 23 under sodium methoxide condition to obtain the target compound I. The method has the advantages of short synthetic route, mild reaction conditions, good stereoselectivity when pivaloyl is used for protection, high yield, but high price of (S) -3-hydroxytetrahydrofuran, and increased cost:
Figure BDA0003397573290000031
the method four: under the acidic condition, the compound 21 undergoes a reduction reaction in a 1, 3-tetramethyl disilyl ether and aluminum trichloride system to obtain a compound 22, the compound 22 undergoes a Grignard reagent exchange reaction with isopropyl magnesium chloride/lithium chloride and then undergoes a nucleophilic addition reaction with an intermediate 3 to obtain a compound 24 under the action of citric acid, the compound 24 undergoes a reaction under the condition of hydrochloric acid-methanol solution to obtain a compound 25, and the compound 25 undergoes a demethoxy reaction under the action of triethylsilane-aluminum trichloride to obtain the target compound:
Figure BDA0003397573290000032
the method has the advantages of short synthetic route, high yield and mild reaction conditions. However, the (S) -3-hydroxytetrahydrofuran is relatively expensive, the synthesis cost is increased, and the post-treatment of the route is relatively complicated.
And a fifth method: patent WO2015101916 takes compound 26, namely 5-iodine (or bromine) -2-chlorobenzaldehyde, and under the protection of nitrogen, n-butyllithium hexane solution is added to realize lithium-halogen exchange, and then the compound is subjected to coupling reaction with compound 27, namely (S) -3- (4-bromophenoxy) tetrahydrofuran to obtain compound 28; or the compound 26 reacts with oxalyl chloride under the catalysis of DMF to obtain a compound 32, the compound 32 reacts with benzene fluoride under the action of Lewis acid aluminum trichloride to obtain a compound 33, and the compound 33 reacts with (S) -3-hydroxytetrahydrofuran under the action of strong alkali potassium tert-butoxide to generate SN 2 Nucleophilic substitution reaction and reduction by sodium borohydride to give compound 28. Triethylamine is used as an acid binding agent, and trimethyl chlorosilane is used for protecting the hydroxyl of the compound 28 to obtain a compound 29; or compound 28 and methanesulfonic acid react to obtain compound 34, at-70 ℃, compound 29 (or compound 34) firstly undergoes lithium-halogen exchange with n-butyllithium, then undergoes nucleophilic addition with compound 3 to obtain compound 30, and the hydroxyl group of compound 30 (or compound 35) is converted into methyl ether by using methanol solution of methanesulfonic acid to obtain compound 31The compound 31 is subjected to removal of two methoxy groups in a triethylsilane and boron trifluoride diethyl etherate solution system to obtain a target compound:
Figure BDA0003397573290000033
the method has the advantages of longer synthetic route, more used reagents, complicated post-treatment, very harsh reaction conditions and no contribution to industrial production.
In view of the problems in the existing preparation of Engliclazide, the research and search of a route which is suitable for industrial production and has the advantages of mild reaction conditions, simple and convenient operation process, high product yield, high purity and low production cost is the problem to be solved at present.
Disclosure of Invention
In order to overcome the defects of the prior art, solve the problems of low reaction temperature and difficult control of sugar and side chains, and effectively remove alpha-configuration impurities in the product to obtain a process more suitable for industrial production, the invention provides a novel Engliflozin intermediate compound and a novel method for preparing Engliflozin by using the novel intermediate.
The specific technical content of the invention is as follows:
in a first aspect, the present invention provides a novel englitjing intermediate compound having the structure shown in formula V:
Figure BDA0003397573290000041
the second aspect of the invention provides a preparation method of the englitjing intermediate compound V: the preparation method of the englitjing intermediate compound V comprises the following steps: adding the compound III and the compound IV into the organic solvent A, and controlling the temperature T under the protection of inert gas 1 Stirring for reaction, adding aluminium trichloride in batches, heating to room temperature for reaction until the reaction is finished, and post-treatingObtaining a compound V:
Figure BDA0003397573290000042
preferably, the organic solvent A is selected from one or a combination of dichloromethane, carbon tetrachloride, chloroform and 1, 2-dichloroethane.
Preferably, the feeding mole ratio of the compound III, the compound IV and the aluminum trichloride is 1:1.0 to 2.0:1.0 to 2.0, preferably 1:1.05:1.2.
Preferably, the reaction temperature T 1 Is at a temperature of between-5 and 5 ℃.
In a preferred scheme, after the reaction is finished, the post-treatment is required, and the specific steps are as follows: after the reaction, 1M diluted hydrochloric acid is added for acidification, an organic phase is separated, an acid water layer is extracted by dichloromethane, the organic layers are combined, the organic layers are washed by water, saturated saline water, dried by anhydrous sodium sulfate, filtered and the solvent is distilled off under reduced pressure, so that the compound V is obtained.
Wherein compound III is prepared as follows:
step 1: adding a compound SM-1, magnesium chips and an organic solvent B into two bottles, stirring and reacting under the protection of inert gas at a low temperature T2, slowly adding a compound IV, and stirring at a temperature of 0 ℃ after adding until the reaction is finished to obtain a compound II;
step 2: adding the compound II, methanesulfonic acid and absolute methanol into a single-neck flask, and stirring at room temperature until the reaction is finished to obtain a compound III:
the synthetic route is as follows:
Figure BDA0003397573290000051
preferably, the organic solvent B in step 1 is selected from one of diethyl ether, tetrahydrofuran and n-hexane.
Preferably, the molar ratio of the compound IV, the compound SM-1 and the magnesium turnings in the step 1 is as follows: 1:1.0 to 1.8:1.0 to 2.0, particularly preferred: 1.0:1.1:1.3.
Preferably, the low temperature T in step 1 2 The method comprises the following steps: -30 to-10 ℃.
Preferably, the molar ratio of the compound II to the methanesulfonic acid in the step 2 is as follows: 1.0:0.08 to 0.5, preferably 1.0:0.1.
In a preferred scheme, after the reaction is finished, the post-treatment is needed, and the post-treatment in the step 1 is as follows: after the reaction, a saturated aqueous ammonium chloride solution was slowly added to quench, ethyl acetate was added, the organic phase was separated, the aqueous phase was extracted with diethyl ether, the organic phases were combined, the organic phase was washed once with water and saturated brine, and the organic phase was dried over anhydrous sodium sulfate. Filtering to remove the drying agent, concentrating under reduced pressure, and evaporating solvent to obtain the compound II.
The post-treatment of the step 2 is as follows: after the reaction, adding sodium bicarbonate, stirring, adding anhydrous sodium sulfate, drying, filtering to remove a drying agent, concentrating under reduced pressure, and evaporating to remove the solvent to obtain a yellow solid compound III.
In a third aspect, the present invention provides a process for the preparation of englitjing, using the novel intermediate compound V:
Figure BDA0003397573290000052
a preparation method of englitjing, comprising the following steps:
step 1: adding a compound V and tetrabutylammonium fluoride into a single-neck flask at room temperature, adding an organic solvent D, and reacting at room temperature until the reaction is finished to obtain a compound VI;
step 2: adding a mixed solvent of a compound VI and dried dichloromethane/acetonitrile into a single-neck flask, and controlling the temperature T 3 And adding ethyl silane and boron fluoride diethyl ether complex, heating to 0 ℃, and stirring until the reaction is finished to obtain the engagliflozin.
Preferably, the organic solvent D in step 1 is selected from one of dry tetrahydrofuran, diethyl ether, acetonitrile and dichloromethane.
Preferably, the molar ratio of the compound V to tetrabutylammonium fluoride in the step 1 is as follows: 1:4.0.0 to 5.0, of which 1 is particularly preferred: 4.2.
preferably, the molar ratio of the compound VI, the ethylsilane and the fluorinated boron diethyl ether complex in the step 2 is as follows: 1:3.5 to 4.5:2.5 to 3.5, of which particular preference is given: 1.0:4.0:3.0.
Preferably, the temperature T in step 2 3 Is at a temperature of between-20 and 0 ℃.
In a preferred scheme, after the reaction is finished, the post-treatment is required, and the specific steps of the step 1 are as follows: after the reaction, the solvent was distilled off by concentrating under reduced pressure, and the crude product was recrystallized from a mixture of ethanol and ethyl acetate (volume ratio 1:1) to give a pale yellow solid compound VI.
The post-treatment specific steps of the step 2 are as follows: after the reaction, the mixture was quenched by slowly adding a saturated aqueous sodium bicarbonate solution, the organic phase was separated, the aqueous phase was extracted with ethyl acetate, the organic phases were combined, the organic phase was washed once with water and saturated brine, and the organic phase was dried over anhydrous sodium sulfate. Filtering to remove the drying agent, concentrating under reduced pressure, evaporating to remove the solvent, and recrystallizing the crude product with a mixed solution of ethanol and ethyl acetate (volume ratio 1:1) to obtain the engagliflozin.
Compared with the prior art, the invention has the technical effects that:
1. provides a new intermediate compound of the enggliflozin, and simultaneously provides a simple and efficient method for preparing the enggliflozin by using the new intermediate, the whole synthesis method has simple and convenient operation, avoids the use of dangerous chemicals such as n-butyl and the like, and has high reaction yield;
2. the process can solve the problems of low reaction temperature and difficult control of sugar and side chains, and effectively remove alpha-configuration impurities in the product;
3. the enggliflozin obtained by the technology has higher purity and yield, and is suitable for industrialized amplified production.
Detailed Description
The invention is further illustrated by the following examples, with the understanding that: the examples of the present invention are intended to be illustrative of the invention and not to be limiting of the invention, so that simple modifications to the invention which are based on the method of the invention are within the scope of the invention as claimed.
The structure of the compound obtained by the invention is confirmed:
Figure BDA0003397573290000071
HPLC peak area normalization method:
chromatographic column: YMC-Triart C 18 Columns (4.6 mm. Times.250 mm,5 μm);
mobile phase: acetonitrile: water (80:20);
column temperature: 30 ℃;
detection wavelength: 210nm;
flow rate: 1.0ml/min;
sample injection amount: 10 μl;
retention time: 16.5min.
High resolution mass spectrum of compound II: ESI-HRMS: m/z=748.7482 [ M+H ]] + ,mp 213～216℃， 1 H-NMR(400MHz,DMSO-d 6 )δ:7.38(d,2H),7.36(d,2H),5.12(br,1H),4.08(d,1H),4.03(d,1H),3.77(d,1H),3.70(dd,1H),3.60(m,2H),0.98(s,36H),0.21(s,24H)； 13 C-NMR(100MHz,DMSO-d 6 )δ:137.7,131.5,128.7,128.6,127.8,127.7,113.8,85.6,80.6,79.2,73.0,63.9,30.9,30.7,30.6,30.5,25.9,25.8,25.7,25.6；
Figure BDA0003397573290000072
Characterization of compound III:
HPLC peak area normalization method:
chromatographic column: YMC-Triart C 18 Columns (4.6 mm. Times.250 mm,5 μm);
mobile phase: acetonitrile: water (80:20);
column temperature: 30 ℃;
detection wavelength: 210nm;
flow rate: 1.0ml/min;
sample injection amount: 10 μl;
retention time: 13.0min.
ESI-HRMS(m/z)：784.7745[M+Na] + .mp 215～218℃； 1 H-NMR(400MHz,DMSO-d 6 )δ:7.38(d,2H),7.37(d,2H),4.28(d,1H),4.03(d,1H),3.77(d,1H),3.70(dd,1H),3.60(m,2H),3.30(s,3H),0.98(s,36H),0.21(s,24H)； 13 C-NMR(100MHz,DMSO-d 6 )δ:137.7,131.5,128.7,128.6,127.8,127.7,121.5,83.1,80.9,79.5,73.0,63.9,30.9,30.7,30.6,30.5,25.9,25.8,25.7,25.6.
Figure BDA0003397573290000081
HPLC peak area normalization method:
chromatographic column: YMC-Triart C18 column (4.6 mm. Times.250 mm,5 μm);
mobile phase: acetonitrile: water (80:20);
column temperature: 30 ℃;
detection wavelength: 210nm;
flow rate: 1.0ml/min;
sample injection amount: 10 μl;
retention time: 12.5min.
ESI-HRMS:m/z＝974.9732[M+Na] + ,mp 235～238℃, 1 H-NMR(400MHz,DMSO-d 6 )δ:7.77(s,1H),7.73(d,2H),7.56(d,1H),7.55(d,1H),7.03(d,2H),4.28(d,1H),4.25(d,1H),4.05(m,1H),4.03(d,1H),4.00(d,1H),3.80(t,1H),3.77(d,1H),3.70(m,2H),3.60(m,2H),3.30(s,3H),2.36(dt,1H),2.11(dt,1H),0.98(s,36H),0.21(s,24H)； 13 C-NMR(100MHz,DMSO-d 6 )δ:196.3,161.1,137.4,136.5,136.2,131.4,131.0,130.9,130.8,130.0,127.2,121.5,114.1,114.0,83.1,80.9,80.8,79.6,79.5,73.0,67.5,63.9,52.4,32.2,30.9,30.2,25.9,25.6.
Figure BDA0003397573290000091
HPLC peak area normalization method:
chromatographic column: YMC-Triart C18 column (4.6 mm. Times.250 mm,5 μm);
mobile phase: acetonitrile: water (80:20);
column temperature: 30 ℃;
detection wavelength: 210nm;
flow rate: 1.0ml/min;
sample injection amount: 10 μl;
retention time: 19.5min.
ESI-HRMS:m/z＝495.9207[M+H] + ,mp 280～283℃, 1 H-NMR(400MHz,DMSO-d 6 )δ:7.78(s,1H),7.70(d,2H),7.56(d,1H),7.55(d,1H),7.03(d,2H),4.28(d,1H),4.25(d,1H),4.05(m,1H),4.03(d,1H),4.00(d,1H),3.80(t,1H),3.77(d,1H),3.70(m,2H),3.60(m,2H),3.30(s,3H),2.36(dt,1H),2.11(dt,1H),0.98(s,36H),0.21(s,24H)； 13 C-NMR(100MHz,DMSO-d 6 )δ:196.3,161.1,137.4,136.5,136.2,131.4,131.0,130.9,130.8,130.0,127.2,121.5,114.1,114.0,83.1,80.9,80.8,79.6,79.5,73.0,67.5,63.9,52.4,32.2,30.9,30.2,25.9,25.6.
Figure BDA0003397573290000092
HPLC peak area normalization method:
chromatographic column: YMC-Triart C18 column (4.6 mm. Times.250 mm,5 μm);
mobile phase: a: acetonitrile, B: gradient elution (0- > 10min: A40%, 10- > 30min: A40% -90%);
column temperature: 35 ℃;
detection wavelength: 224nm;
flow rate: 1.0ml/min;
sample injection amount: 10 μl;
retention time: 16.80min.
ESI-HRMS:m/z＝451.9212[M+H] + ,mp149～152℃, 1 H NMR(400MHz,MeOD)δ:7.36(d,2H),7.28(dd,1H),7.13(d,2H),6.81-6.89(m,2H),4.87-4.94(m,1H),4.11(d,1H),4.00(d,1H),3.95(ddd,5H),3.68(dd,1H),3.36-3.53(m,3H),3.24-3.35(m,2H),2.18(dtd,1H),1.98-2.13(m,1H)。 13 C NMR(400MHz,MeOD)δ:154.9，143.2，137.7，133.1，130.7，130.6，129.1，128.9，128.8，125.4，115.0，114.9，84.8，80.8，79.6，78.7，75.0，71.5，70.2，67.5，62.2，36.5，32.2.
Preparation of Compound II
Example 1
SM-1 (52.46 g,0.22 mol), magnesium turnings (6.41 g,0.26 mol) and dehydrated ether (110 mL) were added to a two-necked flask, and reacted at-20℃for 3 hours under argon atmosphere, compound IV (127.03 g,0.20mol, dissolved in 200mL of dry tetrahydrofuran) was slowly added, and after the addition was completed, the mixture was stirred at constant temperature of 0℃for 4 hours. After the completion of the reaction, a saturated aqueous ammonium chloride solution (250 mL) was slowly added to quench, ethyl acetate (100 mL) was added, the organic phase was separated, the aqueous phase was extracted with diethyl ether (200 mL. Times.3), the organic phases were combined, each of the organic phases was washed once with water and saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The drying agent is removed by filtration, the solvent is evaporated by decompression concentration, and the compound II is obtained with the yield of 98.4 percent and the HPLC purity of 99.92 percent.
Example 2
SM-1 (47.58 g,0.2 mol), magnesium turnings (6.41 g,0.26 mol) and anhydrous tetrahydrofuran (110 mL) were added to a two-necked flask, and the mixture was reacted at-30℃for 3 hours under argon atmosphere, compound IV (127.03 g,0.20mol, dissolved in 200mL of dry tetrahydrofuran) was slowly added, and after the addition was completed, the mixture was stirred at constant temperature of 0℃for 4 hours. After the completion of the reaction, a saturated aqueous ammonium chloride solution (250 mL) was slowly added to quench, ethyl acetate (100 mL) was added, the organic phase was separated, the aqueous phase was extracted with diethyl ether (200 mL. Times.3), the organic phases were combined, each of the organic phases was washed once with water and saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The drying agent was removed by filtration, and the solvent was evaporated under reduced pressure to give compound II in 94.5% yield and 99.62% purity by HPLC.
Example 3
SM-1 (85.64 g,0.36 mol), magnesium turnings (6.41 g,0.26 mol) and anhydrous n-hexane (180 mL) were added to a two-necked flask, and reacted at-10℃for 3 hours under argon atmosphere, compound IV (127.03 g,0.20mol, dissolved in 200mL of dry tetrahydrofuran) was slowly added, and after the addition was completed, the mixture was stirred at constant temperature of 0℃for 4 hours. After the completion of the reaction, a saturated aqueous ammonium chloride solution (250 mL) was slowly added to quench, ethyl acetate (100 mL) was added, the organic phase was separated, the aqueous phase was extracted with diethyl ether (200 mL. Times.3), the organic phases were combined, each of the organic phases was washed once with water and saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The drying agent is removed by filtration, the solvent is evaporated by vacuum concentration, and the compound II is obtained with the yield of 94.8 percent and the HPLC purity of 99.48 percent.
Example 4
SM-1 (52.46 g,0.22 mol), magnesium turnings (4.86 g,0.2 mol) and anhydrous tetrahydrofuran (110 mL) were added to a two-necked flask, and the mixture was reacted at-30℃for 3 hours under argon atmosphere, compound IV (127.03 g,0.20mol, dissolved in 200mL of dry tetrahydrofuran) was slowly added, and after the addition was completed, the mixture was stirred at constant temperature of 0℃for 4 hours. After the completion of the reaction, a saturated aqueous ammonium chloride solution (250 mL) was slowly added to quench, ethyl acetate (100 mL) was added, the organic phase was separated, the aqueous phase was extracted with diethyl ether (200 mL. Times.3), the organic phases were combined, each of the organic phases was washed once with water and saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The drying agent is removed by filtration, the solvent is evaporated by vacuum concentration, and the compound II is obtained with the yield of 94.5% and the HPLC purity of 99.45%.
Example 5
SM-1 (52.46 g,0.22 mol), magnesium turnings (9.72 g,0.4 mol) and tetrahydrofuran (110 mL) were added to a two-necked flask, and reacted at-10℃for 3 hours under argon, compound IV (127.03 g,0.20mol, dissolved in 200mL of dry tetrahydrofuran) was slowly added, and after the addition, the mixture was stirred at constant temperature of 0℃for 4 hours. After the completion of the reaction, a saturated aqueous ammonium chloride solution (250 mL) was slowly added to quench, ethyl acetate (100 mL) was added, the organic phase was separated, the aqueous phase was extracted with diethyl ether (200 mL. Times.3), the organic phases were combined, each of the organic phases was washed once with water and saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The drying agent is removed by filtration, the solvent is distilled off by vacuum concentration, and the compound II is obtained with the yield of 95.5 percent and the HPLC purity of 99.32 percent.
Example 6
SM-1 (95.16 g,0.4 mol), magnesium turnings (10.69 g,0.44 mol) and dehydrated ether (200 mL) were added to a two-necked flask, and reacted at-20℃for 3 hours under argon atmosphere, compound IV (127.03 g,0.20mol, dissolved in 200mL of dry tetrahydrofuran) was slowly added, and after the addition was completed, the mixture was stirred at constant temperature of 0℃for 4 hours. After the completion of the reaction, a saturated aqueous ammonium chloride solution (250 mL) was slowly added to quench, ethyl acetate (100 mL) was added, the organic phase was separated, the aqueous phase was extracted with diethyl ether (200 mL. Times.3), the organic phases were combined, each of the organic phases was washed once with water and saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The drying agent is removed by filtration, the solvent is distilled off by concentration under reduced pressure, and the compound II is obtained with the yield of 88.6% and the HPLC purity of 98.87%.
Preparation of Compound III
Example 7
To a single vial was added compound II (112.16 g,0.15 mol), methanesulfonic acid (1.44 g,15 mmol) and anhydrous methanol (75 mL) and dissolved with stirring, and reacted at room temperature for 2 hours. After the reaction, sodium hydrogencarbonate (1.3 g) was added and stirred for 30 minutes, then anhydrous sodium sulfate was added and dried, the drying agent was removed by filtration, and the solvent was distilled off by concentration under reduced pressure to obtain compound III in a yield of 98.9% and an HPLC purity of 99.89%.
Example 8
To a single vial was added compound II (112.16 g,0.15 mol), methanesulfonic acid (1.15 g,12 mmol) and anhydrous methanol (75 mL) and the mixture was dissolved with stirring and reacted at room temperature for 2 hours. After the reaction, sodium hydrogencarbonate (1.2 g) was added and stirred for 30 minutes, then anhydrous sodium sulfate was added and dried, the drying agent was removed by filtration, and the solvent was distilled off by concentration under reduced pressure to obtain compound III in a yield of 94.6% and an HPLC purity of 99.63%.
Example 9
To a single vial was added compound II (112.16 g,0.15 mol), methanesulfonic acid (7.2 g,75 mmol) and anhydrous methanol (120 mL) and the mixture was dissolved with stirring and reacted at room temperature for 2 hours. After the reaction, sodium bicarbonate (1.2 g) was added and stirred for 30 minutes, then anhydrous sodium sulfate was added and dried, the drying agent was removed by filtration, and the solvent was distilled off by concentration under reduced pressure to obtain compound III in a yield of 95.3% and an HPLC purity of 99.55%.
Example 10
To a single vial was added compound II (112.16 g,0.15 mol), methanesulfonic acid (0.86 g,9.0 mmol) and anhydrous methanol (75 mL) and the mixture was dissolved with stirring and reacted at room temperature for 2 hours. After the reaction, sodium hydrogencarbonate (0.76 g) was added and stirred for 30 minutes, then anhydrous sodium sulfate was added and dried, the drying agent was removed by filtration, and the solvent was distilled off by concentration under reduced pressure to give compound III in 88.9% yield and 98.69% purity by HPLC.
Example 11
To a single flask, compound II (112.16 g,0.15 mol), methanesulfonic acid (2.55 g,105 mmol) and anhydrous methanol (75 mL) were added and dissolved with stirring, and reacted at room temperature for 2 hours. After the reaction, sodium hydrogencarbonate (8.82 g) was added and stirred for 30 minutes, then anhydrous sodium sulfate was added and dried, the drying agent was removed by filtration, and the solvent was distilled off by concentration under reduced pressure to give compound III in a yield of 84.7% and an HPLC purity of 98.23%.
Preparation of Compound V
Example 12
To a two-port flask, compound III (76.18 g,0.10 mol), compound IV (23.37 g,0.105 mol) and dry dichloromethane (150 mL) were added, and the mixture was stirred at 0℃for 30 minutes under argon atmosphere, aluminum trichloride (16.00 g,0.12 mol) was added in portions, and after the addition was completed, the mixture was allowed to stand at room temperature for 5 hours. After the reaction, 1.0mol/L dilute hydrochloric acid (100 mL) was added for acidification, the organic phase was separated, the acid-water layer was extracted with dichloromethane (150 mL. Times.3), the organic layers were combined, washed with water, saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was distilled off under reduced pressure to remove the solvent, to give Compound V in 98.9% yield and 99.95% HPLC purity.
Example 13
To a two-port flask, compound III (76.18 g,0.10 mol), compound IV (22.60 g,0.10 mol) and dry carbon tetrachloride (150 mL) were added, and the mixture was stirred at-5℃under argon for 30 minutes, aluminum trichloride (16.00 g,0.12 mol) was added in portions, and after the addition was completed, the mixture was warmed to room temperature and reacted for 5 hours. After the reaction, 1.0mol/L dilute hydrochloric acid (100 mL) was added for acidification, the organic phase was separated, the aqueous acid layer was extracted with dichloromethane (150 mL. Times.3), the organic layers were combined, washed with water, saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was distilled off under reduced pressure to remove the solvent, to give Compound V in a yield of 94.1% and an HPLC purity of 99.51%.
Example 14
To a two-port flask, compound III (76.18 g,0.10 mol), compound IV (45.2 g,0.20 mol) and dried chloroform (150 mL) were added, and the mixture was stirred at 5℃for 30 minutes under argon atmosphere, aluminum trichloride (16.00 g,0.12 mol) was added in portions, and after the addition was completed, the mixture was warmed to room temperature and reacted for 5 hours. After the reaction, 1.0mol/L dilute hydrochloric acid (100 mL) was added for acidification, the organic phase was separated, the acid-water layer was extracted with dichloromethane (150 mL. Times.3), the organic layers were combined, washed with water, saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was distilled off under reduced pressure to remove the solvent, to give Compound V in a yield of 95.2% and an HPLC purity of 99.40%.
Example 15
To a two-port flask, compound III (76.18 g,0.10 mol), compound IV (23.37 g,0.105 mol) and dry 1, 2-dichloroethane (150 mL) were added, and under argon, aluminum trichloride (15.14 g,0.1 mol) was added in portions with stirring at-5℃for 30 minutes, and after the addition was completed, the reaction was allowed to proceed to room temperature for 5 hours. After the reaction, 1.0mol/L dilute hydrochloric acid (100 mL) was added for acidification, the organic phase was separated, the acid-water layer was extracted with dichloromethane (150 mL. Times.3), the organic layers were combined, washed with water, saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was distilled off under reduced pressure to remove the solvent, to give Compound V in a yield of 93.9% and an HPLC purity of 99.65%.
Example 16
To a two-port flask, compound III (76.18 g,0.10 mol), compound IV (23.37 g,0.105 mol) and dry dichloromethane (180 mL) were added, and the mixture was stirred at 5℃for 30 minutes under argon atmosphere, aluminum trichloride (30.28 g,0.2 mol) was added in portions, and after the addition was completed, the mixture was warmed to room temperature and reacted for 5 hours. After the reaction, 1.0mol/L dilute hydrochloric acid (100 mL) was added for acidification, the organic phase was separated, the acid-water layer was extracted with dichloromethane (150 mL. Times.3), the organic layers were combined, washed with water, saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was distilled off under reduced pressure to remove the solvent, to give Compound V in a yield of 94.1% and an HPLC purity of 99.44%.
Example 17
To a two-port flask, compound III (76.18 g,0.10 mol), compound IV (49.73 g,0.22 mol) and dried dichloromethane (200 mL) were added, and under argon atmosphere, the mixture was stirred at 10℃for 30 minutes, aluminum trichloride (33.30 g,0.22 mol) was added in portions, and after the addition was completed, the mixture was warmed to room temperature and reacted for 5 hours. After the reaction, 1.0mol/L dilute hydrochloric acid (100 mL) was added for acidification, the organic phase was separated, the acid-water layer was extracted with dichloromethane (150 mL. Times.3), the organic layers were combined, washed with water, saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was distilled off under reduced pressure to remove the solvent, to give Compound V in a yield of 88.1% and an HPLC purity of 98.84%.
Preparation of Compound VI
Example 18
To a single-port flask, compound IV (47.60 g,0.05 mol), tetrabutylammonium fluoride (210 mL,0.21mol,1mol/LTHF solution) and dry tetrahydrofuran (100 mL) were added, and after the reaction was completed, the solvent was distilled off by concentration under reduced pressure, and the crude product was recrystallized from a mixture of ethanol and ethyl acetate (volume ratio 1:3) to give Compound IV as a pale yellow solid, yield 99.8% and HPLC purity 99.94%.
Example 19
To a single-port flask, compound IV (47.60 g,0.05 mol), tetrabutylammonium fluoride (200 mL,0.20mol,1mol/LTHF solution) and dry diethyl ether (100 mL) were added, and after the reaction was completed at room temperature for 1 hour, the solvent was distilled off by concentration under reduced pressure, and the crude product was recrystallized from a mixture of ethanol and ethyl acetate (volume ratio 1:3) to give Compound IV as a pale yellow solid, yield 98.2% and HPLC purity 99.89%.
Example 20
To a single-port flask, compound IV (47.60 g,0.05 mol), tetrabutylammonium fluoride (250 mL,0.25mol,1mol/LTHF solution) and dry acetonitrile (100 mL) were added, and after the reaction was completed at room temperature for 1 hour, the solvent was distilled off by concentration under reduced pressure, and the crude product was recrystallized from a mixture of ethanol and ethyl acetate (volume ratio 1:3) to give Compound IV as a pale yellow solid in 96.4% yield with a HPLC purity of 99.65%.
Example 21
To a single-port flask, compound IV (47.60 g,0.05 mol), tetrabutylammonium fluoride (175 mL,0.175mol,1mol/LTHF solution) and dried dichloromethane (100 mL) were added, and after the reaction was completed at room temperature for 1 hour, the solvent was distilled off by concentration under reduced pressure, and the crude product was recrystallized from a mixture of ethanol and ethyl acetate (volume ratio 1:3) to give Compound IV as a pale yellow solid in a yield of 88.9% and an HPLC purity of 98.85%.
Example 22
To a single-port flask, compound IV (47.60 g,0.05 mol), tetrabutylammonium fluoride (275 mL,0.275mol,1mol/LTHF solution) and dried dichloromethane (100 mL) were added, and after the reaction was completed, the solvent was distilled off by concentration under reduced pressure, and the crude product was recrystallized from a mixture of ethanol and ethyl acetate (volume ratio 1:3) to give Compound IV as a pale yellow solid in a yield of 89.3% and an HPLC purity of 98.66%.
Preparation of Engliflozin
Example 23
To a single vial was added compound VI (9.89 g,0.02 mol) with dry dichloromethane and acetonitrile (V Dichloromethane (dichloromethane) ∶V Acetonitrile Dissolving with stirring (1:1, 50 mL), cooling to-10deg.C, sequentially adding ethyl silane (4.81 g,0.08 mol), boron trifluoride diethyl etherate (8.51 g,0.06 mol), slowly raising to 0deg.C, and reacting at constant temperature for 5 hr. After completion of the reaction, the mixture was quenched by slowly adding a saturated aqueous sodium hydrogencarbonate solution (150 mL), the organic phase was separated, the aqueous phase was extracted with ethyl acetate (200 mL. Times.3), the organic phases were combined, each of the organic phases was washed with water and saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The drying agent is removed by filtration, the solvent is distilled off by decompression concentration, and the crude product is recrystallized by mixed solution of ethanol and ethyl acetate (volume ratio is 1:1) to obtain the Enagliflozin with the yield of 99.5 percent and the HPLC purity of 99.98 percent.
Example 24
To a single vial was added compound VI (9.89 g,0.02 mol) with dry dichloromethane and acetonitrile (V Dichloromethane (dichloromethane) ∶V Acetonitrile Dissolving with stirring (1:1, 50 mL), cooling to-20deg.C, adding ethyl silane (4.21 g,0.07 mol) and boron trifluoride diethyl etherate (7.10 g,0.05 mol) in sequence, slowly raising to 0deg.C, and reacting at constant temperature for 5 hours. After completion of the reaction, the mixture was quenched by slowly adding a saturated aqueous sodium hydrogencarbonate solution (150 mL), the organic phase was separated, the aqueous phase was extracted with ethyl acetate (200 mL. Times.3), the organic phases were combined, each of the organic phases was washed with water and saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The drying agent is removed by filtration, the solvent is distilled off by decompression concentration, and the crude product is recrystallized by mixed solution of ethanol and ethyl acetate (volume ratio is 1:1) to obtain the Enagliflozin with the yield of 96.1 percent and the HPLC purity of 99.62 percent.
Example 25
To a single vial was added compound VI (9.89 g,0.02 mol) with dry dichloromethane and acetonitrile (V Dichloromethane (dichloromethane) ∶V Acetonitrile Stirring and dissolving the mixture, cooling the mixture to 0 ℃, adding ethyl silane (5.42 g,0.09 mol) and boron trifluoride diethyl etherate (9.94 g,0.07 mol) in sequence, slowly raising the mixture to 0 ℃, and reacting the mixture at constant temperature for 5 hours. After the reaction, a saturated aqueous sodium hydrogencarbonate solution (150 mL) was slowly added to quench the reaction, and the organic phase was separatedThe aqueous phase was extracted with ethyl acetate (200 mL. Times.3), the organic phases were combined, each washed once with water and saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The drying agent is removed by filtration, the solvent is distilled off by decompression concentration, and the crude product is recrystallized by mixed solution of ethanol and ethyl acetate (volume ratio is 1:1) to obtain the Enagliflozin with the yield of 96.8 percent and the HPLC purity of 99.58 percent.
Example 26
To a single vial was added compound VI (9.89 g,0.02 mol) with dry dichloromethane and acetonitrile (V Dichloromethane (dichloromethane) ∶V Acetonitrile Stirring and dissolving the mixture, cooling the mixture to-25 ℃, sequentially adding ethyl silane (3.61 g,0.06 mol) and boron trifluoride diethyl etherate (5.68 g,0.04 mol), slowly raising the temperature to 0 ℃, and reacting the mixture at constant temperature for 5 hours. After completion of the reaction, the mixture was quenched by slowly adding a saturated aqueous sodium hydrogencarbonate solution (150 mL), the organic phase was separated, the aqueous phase was extracted with ethyl acetate (200 mL. Times.3), the organic phases were combined, each of the organic phases was washed with water and saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The drying agent is removed by filtration, the solvent is distilled off by decompression concentration, and the crude product is recrystallized by mixed solution of ethanol and ethyl acetate (volume ratio is 1:1) to obtain the Enagliflozin with the yield of 88.8 percent and the HPLC purity of 98.88 percent.
Example 27
To a single vial was added compound VI (9.89 g,0.02 mol) with dry dichloromethane and acetonitrile (V Dichloromethane (dichloromethane) ∶V Acetonitrile Stirring and dissolving the mixture, cooling the mixture to 5 ℃, adding ethyl silane (6.01 g,0.1 mol) and boron trifluoride diethyl etherate (11.35 g,0.08 mol) in sequence, slowly raising the temperature to 0 ℃ and reacting the mixture at constant temperature for 5 hours. After completion of the reaction, the mixture was quenched by slowly adding a saturated aqueous sodium hydrogencarbonate solution (150 mL), the organic phase was separated, the aqueous phase was extracted with ethyl acetate (200 mL. Times.3), the organic phases were combined, each of the organic phases was washed with water and saturated brine, and the organic phase was dried over anhydrous sodium sulfate. The drying agent is removed by filtration, the solvent is distilled off by decompression concentration, and the crude product is recrystallized by mixed solution of ethanol and ethyl acetate (volume ratio is 1:1) to obtain the Enagliflozin with the yield of 89.4 percent and the HPLC purity of 98.45 percent.

Claims (10)

1. An englitjing intermediate compound is characterized in that the structure of the englitjing intermediate compound is shown as a formula V:
Figure FDA0003397573280000011
2. a process for the preparation of the engagliflozin intermediate compound V according to claim 1, comprising the steps of: adding the compound III and the compound IV into the organic solvent A, and controlling the temperature T under the protection of inert gas 1 Stirring for reaction, adding aluminum trichloride in batches, reacting at room temperature until the reaction is finished, and performing post-treatment on the reaction to obtain a compound V:
the synthetic route is as follows:
Figure FDA0003397573280000012
3. the preparation method according to claim 2, wherein the organic solvent A is selected from one or a combination of dichloromethane, carbon tetrachloride, chloroform and 1, 2-dichloroethane.
4. The preparation method according to claim 2, wherein the feeding molar ratio of the compound III, the compound IV and the aluminum trichloride is 1:1.0 to 2.0:1.0 to 2.0; the reaction temperature T 1 Is at a temperature of between-5 and 5 ℃.
5. The preparation method according to claim 2, wherein the preparation method of the compound III comprises the steps of:
step 1: adding compound SM-1, magnesium chips and organic solvent B into two bottles, and under the protection of inert gas, performing low-temperature T 2 Stirring for reaction under the condition, slowly adding the compound IV, and controlling the temperature to be 0 ℃ after the addition is finished, and stirring until the reaction is finished to obtain a compound II;
step 2: adding the compound II, methanesulfonic acid and absolute methanol into a single-neck flask, and stirring at room temperature until the reaction is finished to obtain a compound III:
the synthetic route is as follows:
Figure FDA0003397573280000013
6. the preparation method according to claim 5, wherein the compound IV, the compound SM-1 and the magnesium chips in the step 1 are fed in a molar ratio of: 1:1.0 to 1.8:1.0 to 2.0; the feeding mole ratio of the compound II to the methanesulfonic acid in the step 2 is as follows: 1.0:0.08-0.5.
7. The preparation method according to claim 5, wherein the organic solvent B in the step 1 is selected from one of diethyl ether, tetrahydrofuran and n-hexane; the low temperature T in step 1 2 The method comprises the following steps: -30 ℃ to-10 ℃.
8. Use of an englitazone intermediate compound of claim 1 for the preparation of englitazone.
9. Use of an england intermediate compound of claim 8 for the preparation of england, characterized in that the preparation process comprises the steps of:
step 1: adding a compound V and tetrabutylammonium fluoride into a single-neck flask at room temperature, adding an organic solvent D, and reacting at room temperature until the reaction is finished to obtain a compound VI;
step 2: adding a mixed solvent of a compound VI and dried dichloromethane/acetonitrile into a single-neck flask, and controlling the temperature T 3 Adding ethyl silane and boron fluoride diethyl ether complex, heating to 0 ℃, stirring until the reaction is finished, and obtaining the englitjing:
Figure FDA0003397573280000021
10. the use according to claim 9, wherein the compound V, tetrabutylammonium fluoride in step 1 is fed in a molar ratio of: 1:4.0.0-5.0; the feeding mole ratio of the compound VI, the ethyl silane and the boron fluoride diethyl ether complex in the step 2 is as follows: 1:3.5-4.5:2.5-3.5; the organic solvent D in the step 1 is selected from one of dry tetrahydrofuran, diethyl ether, acetonitrile and dichloromethane; the temperature T in step 2 3 Is at a temperature of between-20 and 0 ℃.
CN202111516828.9A 2021-12-07 2021-12-07 Engliflozin intermediate compound Pending CN116239643A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111516828.9A CN116239643A (en) 2021-12-07 2021-12-07 Engliflozin intermediate compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111516828.9A CN116239643A (en) 2021-12-07 2021-12-07 Engliflozin intermediate compound

Publications (1)

Publication Number Publication Date
CN116239643A true CN116239643A (en) 2023-06-09

Family

ID=86622980

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111516828.9A Pending CN116239643A (en) 2021-12-07 2021-12-07 Engliflozin intermediate compound

Country Status (1)

Country Link
CN (1) CN116239643A (en)

Similar Documents

Publication Publication Date Title
CN114524795B (en) Improved rhodozyrtone preparation method
CN111704573B (en) Preparation method of rabeprazole chloride and intermediate thereof
CN112812107B (en) Preparation method of SGLT-2 inhibitor and intermediate
JP3231765B2 (en) Method for producing demethyl epipodophyllotoxin
CN111217828B (en) Preparation method of lepistamycin and intermediate thereof
CN111057032B (en) Preparation method of dapagliflozin
CN116239643A (en) Engliflozin intermediate compound
CN109836465B (en) Method for preparing epirubicin hydrochloride
CN113004300B (en) Stable isotope labeled patulin and synthesis method thereof
CN111100042B (en) Preparation method of 2-methoxy-5-sulfonamide benzoic acid
CN110386958B (en) Preparation method of fondaparinux sodium intermediate
CN116239582A (en) Engliflozin intermediate compound and preparation method thereof
CN113816837A (en) Synthesis method of 4,4' -dimethoxy triphenylchloromethane
CN108948105B (en) Chemical synthesis method of glycyrrhetinic acid monoglucuronide
CN109111490B (en) Halogenated pivaloyl glucopyranose and preparation method thereof for SGLT2 inhibitor
CN114560901B (en) Preparation method of ergosterol or derivative thereof
CN113683650A (en) Preparation method of beta-D- (1,4) -mannuronic acid oligosaccharide and intermediate thereof
CN114380779A (en) Preparation method of dapagliflozin impurity
CN110746471B (en) Preparation method of fondaparinux sodium disaccharide intermediate
CN113372274B (en) Preparation method of ivabradine
CN113248464B (en) Synthesis method of C-glycoside derivatives
CN113372273B (en) Ivabradine intermediate compound IV
CN114478659B (en) Preparation method of disaccharide compound
CN117756610A (en) Synthesis method of dapagliflozin intermediate
CN117756611A (en) Preparation method of dapagliflozin intermediate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication